LivingGLP1
Study S000283

Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial

ClinicalTrials.gov record

Registration

Registration
NCT03017352
Acronym
MAG1C
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
108
Start
2016-12
Primary completion
2019-06
Lead sponsor
Filip Krag Knop
Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG:Exenatide; DRUG:Placebos
Results posted
FALSE

Registered primary outcomes

  • Change in HbA1c [6 months]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0051791801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes
N Dyrby Johansen, Diabetes
2023Randomized trialDOIcites ClinicalTrials.gov:NCT03017352
R0053199745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes
N Dyrby Johansen, Diabetes
2022Randomized trialDOIcites ClinicalTrials.gov:NCT03017352
R0015226Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Johansen NJ, The lancet. Diabetes & endocrinology
2020Randomized trialPMID 32135138DOIcites ClinicalTrials.gov:NCT03017352; registry reference DERIVED:32135138
R0014676Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
Johansen NJ, BMJ open
2018ProtocolPMID 29950475DOIcites ClinicalTrials.gov:NCT03017352; registry reference BACKGROUND:29950475